Emerging mechanisms for secondary cardioprotective effects of statins.
Miller
S J
SJ
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use; D002448:Cell Adhesion / Q000187:drug effects; D003327:Coronary Disease / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D009389:Neovascularization, Pathologic; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D011973:Receptors, LDL / Q000378:metabolism; D051131:Receptors, Oxidized LDL; D051127:Scavenger Receptors, Class E
D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D000991:Antithrombins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C495137:OLR1 protein, human; D011518:Proto-Oncogene Proteins; D011973:Receptors, LDL; D051131:Receptors, Oxidized LDL; D051127:Scavenger Receptors, Class E; D009569:Nitric Oxide; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt